+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

GCC Pharmaceutical Market Opportunity Insight 2025

  • ID: 4911941
  • Report
  • January 2020
  • Region: Middle East
  • 300 Pages
  • Kuick Research
1 of 3

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • ACDIMA
  • Bahrain Pharma
  • Gulf Biotech
  • Novartis
  • Qatar Pharma
  • Tabuk Pharmaceuticals
  • MORE

 "GCC Pharmaceutical Market Opportunity Insight 2025" Report Highlights:

  • GCC Pharmaceutical Market Opportunity: > US$ 20 Billion
  • Patented & OTC Pharmaceutical Market Size: 75% of Total Market
  • Share of Imported Drugs In GCC Pharmaceutical Market: > 80%
  • Saudi Arabia Dominates GCC Pharmaceutical Market: 50% Market Share
  • GCC Pharmaceutical Clinical Trials Insight:  > 700 Drugs

The research report "GCC Pharmaceutical Market Opportunity Insight 2025" provides an in-depth analysis about the current market dynamics that includes drivers, trends and opportunities which are subjected to have an influence on the market of the pharmaceutical products in the GCC region. Various important factors that are supported by the governments of the GCC countries for various agents commercialized in the region are also provided in a segmented way in the research report. The impact of the regulatory scenario that is prevailing upon the major key players of the region is also discussed in the report.

The research conducted on the respective subject highlights the distribution of the market based on the profiles of the companies and their respective efforts in increasing the production and value of the product exponentially. The anticipation of the pharmaceutical market in the GCC region is believed to be the result of the factors that are hindering the people of GCC region such as rapid change in the dynamics of the population, geriatric population and most importantly increasing prevalence of lifestyle associated diseases such as diabetes, obesity, cardiovascular diseases.

"GCC Market Offers Unexplored & Exponential Growth Opportunities For Global Pharmaceutical Companies As Imports Accounts For More Than 80% Regional Pharmaceutical Products Sales."

With the increasing disorders associated with lifestyle of the gulf population, the government policies along with regulatory framework became more poised towards the promoting the growth of the pharmaceutical market in the region. Factors like these are most prominent in developing a huge difference and marking an exponential growth rate in the market size of GCC pharmaceutical market in the coming years. Over the years, the branded drugs market has been dominating the market of GCC pharmaceuticals and most pre-dominantly among all the countries included in GCC, Saudi Arabia compiled of maximum share of the market.  

Saudi Arabia, among the other gulf countries is a region with major dominant traits. Economic viability, changing legislative and framework are the main driving forces for the establishment of such high-valued pharmaceutical market in the gulf. Slowly and steadily, new frontiers of the pharmaceutical market are making their way to the gulf and imposing their need for the development of generic drug over the market of branded drugs. The alternative form of the drugs available in the market will end up in the up-regulation of the overall market trends by many folds.

"The Growing Demand Of The Generic And Branded Pharmaceuticals That Is Driven By The Various Government Policies And Cost Effective Facilities, Is Considered As A Significant Opportunity For The Drug Manufacturers In The GCC."

The sales record achieved from the gulf countries establishes Saudi Arabia as an emerging ground for the pharmaceutical market, with UAE and others as a prominent region for expanding the market. The Imported drug market established in the region constitutes a major portion of the GCC pharmaceutical market. More than 80% of the drug utilized in the gulf countries is imported from the major players established in the Western countries. The percent mentioned indicates a huge demand of the drugs either imported or manufactured in the local region. Both aspects of the pharmaceutical market suggest a high demand of the pharmaceutical drugs in the market and eventually a prevailing commercial success.

Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • ACDIMA
  • Bahrain Pharma
  • Gulf Biotech
  • Novartis
  • Qatar Pharma
  • Tabuk Pharmaceuticals
  • MORE

1. Introduction to Gulf Cooperation Council (GCC) Pharmaceutical Market
1.1 Overview
1.2 GCC Pharmaceutical Market Analysis

2. GCC Pharmaceutical Market by Indication - Prevalence & Statistics
2.1 Cancer
2.1.1 Overview
2.1.2 Prevalence by Cancer Type & Gender
2.1.3 Cancer Prevalence & Statistics by GCC Countries
2.2 Diabetes
2.3 HIV/AIDS
2.4 Cardiovascular Diseases
2.4.1 Coronary Heart Disease
2.4.2 Hypertension
2.4.3 Stroke
2.5 Obesity
2.6 Respiratory Disorders
2.6.1 Asthma
2.6.2 Tuberculosis
2.6.3 Influenza & Pneumonia
2.6.4 Other Respiratory Diseases - COPD & Cystic Fibrosis
2.7 Alzheimer's Disease/Dementia

3. GCC - Regulatory Aspects of Pharmaceuticals
3.1 Gulf Central Committee for Drug Registrations (GCC-DR)
3.2 Regulatory Review Process
3.3 Centralized Registration
3.4 Decentralized Drug Registration Regulation
3.4.1 Saudi Arabia
3.4.2 Kuwait
3.4.3 UAE
3.4.4 Bahrain
3.4.5 Qatar
3.4.6 Oman
3.5 Gulf Joint Procurement Program

4. GCC - Pharmaceutical Pricing & Reimbursement Policies
4.1 Pricing Policies
4.1.1 In-Patent Pharmaceuticals
4.1.2 Off-Patent & Generic Pharmaceuticals
4.1.3 Locally & Multinational Manufactured Pharmaceuticals
4.2 Procurement & Reimbursement Policies
4.2.1 In-Patent Pharmaceuticals
4.2.2 Off-Patent, Generics & Biosimilars

5. GCC Pharmaceutical Market by Product
5.1Generics Pharmaceuticals
5.2 Patented & OTC Pharmaceuticals
5.3 Biosimilars

6. Saudi Arabia Pharmaceutical Market Analysis
6.1 Overview
6.2 Saudi Arabia Pharmaceutical Market by Products
6.3 Saudi Arabia Pharmaceutical Market by Companies
6.4 Saudi Arabia Pharmaceutical Market by Type

7. UAE Pharmaceutical Market Analysis
7.1 Overview
7.2 UAE Pharmaceuticals Market by Product
7.3 UAE Pharmaceutical Market by Companies
7.4 UAE Pharmaceutical Market by Type

8. Kuwait Pharmaceutical Market Analysis
8.1 Overview
8.2 Kuwait Pharmaceutical Market by Therapeutic Indication & Products
8.3 Kuwait Pharmaceutical Market by Companies
8.4 Kuwait Pharmaceutical Market by Type

9. Bahrain Pharmaceutical Market Analysis
9.1 Overview
9.2 Bahrain Pharmaceutical Market by Products
9.3 Bahrain Pharmaceutical market by Companies
9.4 Bahrain Pharmaceutical Market by Product Type

10. Qatar Pharmaceutical Market Analysis
10.1 Overview
10.2 Qatar Pharmaceutical Market by Type

11. Oman Pharmaceutical Market Analysis
11.1 Overview
11.2 Oman Pharmaceutical Market by Product Type

12. GCC Pharmaceutical Market - International Trade
12.1 Import Market
12.2 Pharmaceutical Export Market

13. GCC Pharmaceutical Market - Clinical Insight
13.1 Overview
13.2 Clinical Trials by Indication
13.2.1 Cancer
13.2.2 Diabetes
13.2.3 CVS Disorders
13.2.4 Respiratory Disorders
13.3 Clinical Insight by GCC Countries
13.3.1 Saudi Arabia
13.3.2 United Arab Emirates
13.3.3 Kuwait
13.3.4 Bahrain
13.3.5 Qatar
13.3.6 Oman

14. GCC Pharmaceutical Market Drivers

15. Challenges for GCC Pharmaceutical Market

16. GCC Pharmaceutical Market Future Outlook - Trends & Opportunities

17. Competitive Landscape
17.1 Local Pharmaceutical Companies
17.1.1 Julphur Pharmaceuticals
17.1.2 SPIMACO Addwaeih
17.1.3 Qatar Life Pharma
17.1.4 Al Mojil Drug Company
17.1.5 Kuwait Saudi Pharmaceutical Company
17.1.6 YIACO Medical Company
17.1.7 Qatar Pharma
17.1.8 Saja Pharmaceuticals
17.1.9 Oman Pharmaceuticals
17.1.10 Taiba Pharmaceuticals
17.1.11 Gulf Biotech
17.1.12 Bahrain Pharma
17.1.13 Neopharma
17.1.14 Planet Pharmacies
17.1.15 Aljazeera Pharmaceutical Industries
17.1.16 Dallah Pharma
17.1.17 Tabuk Pharmaceuticals
17.1.18 CAD Middle-East Pharmaceutical Company
17.1.19 ACDIMA
17.1.20 AL-Mufid Pharmaceuticals
17.2 Multinational Companies
17.2.1 Novartis
17.2.2 Amgen
17.2.3 Eli - Lilly
17.2.4 Merck
17.2.5 Pfizer
17.2.6 GlaxoSmithKline plc
17.2.7 Roche
17.2.8 Takeda Pharmaceuticals
17.2.9 Teva Pharmaceuticals
17.2.10 AstraZeneca plc
17.2.11 Genentech
17.2.12 Sanofi

List of Figures

Figure 1-1: Pharmaceutical Market Size - Global vs. GCC (US$ Billion), 2018
Figure 1-2: GCC vs. Rest of World - Pharmaceutical Market Size (%), 2018
Figure 1-3: GCC - Population Statistics (Million), 2019
Figure 1-4: GCC - Population by Countries (%), 2019
Figure 1-5: GCC - Healthcare Expenditure by Countries (US$ Billion), 2018
Figure 1-6: GCC - Healthcare Expenditure by Countries (%), 2018
Figure 1-7: GCC - Pharmaceutical Market Size (US$ Billion), 2016 & 2018
Figure 1-8: GCC Pharmaceutical Market Size (US$ Billion), 2018 - 2025
Figure 1-9: MEA vs. GCC - Pharmaceutical Market Size (US$ Billion), 2018
Figure 1-10: GCC vs. Rest of MEA - Pharmaceutical Market Size (%), 2018
Figure 1-11: GCC - Pharmaceutical Market Size by Countries (US$ Billion), 2018
Figure 1-12: Pharmaceutical Market Size of Various GCC Countries (%), 2018
Figure 2-1: GCC - Number of Newly Diagnosed Cancer Cases & Deaths, 2018
Figure 2-2: GCC - Number of New Cancer Cases by Countries, 2018
Figure 2-3: GCC - New Cancer Cases by Countries (%), 2018
Figure 2-4: GCC - Number of Cancer Related Deaths by Countries, 2018
Figure 2-5: GCC - New Cancer Cases by Countries (%), 2018
Figure 2-6: GCC - Number of Newly Diagnosed Cancer Cases, 2018 & 2030
Figure 2-7: GCC - Age Standardized Cancer Incidence Rate by Countries (per 100,000 People), 2018
Figure 2-8: GCC - Age Standardized Cancer Mortality Rate by Countries (per 100,000 People), 2018
Figure 2-9: GCC Pharmaceutical Market Size - Total vs. Cancer Drugs (US$ Billion), 2018
Figure 2-10: GCC - Cancer Drug Market Size by Countries (%), 2018
Figure 2-11: GCC - Number of New Diagnosed Cases by Cancer Type, 2018
Figure 2-12: GCC - New Diagnosed Cases by Cancer Type (%), 2018
Figure 2-13: GCC - Number of Cancer Cases & Deaths by Gender, 2018
Figure 2-14: GCC - Cancer Cases by Gender (%), 2018
Figure 2-15: GCC - Cancer Deaths by Gender (%), 2018
Figure 2-16: GCC - Age Standardized Cancer Incidence & Mortality Rate (per 100,000 People), 2018
Figure 2-17: Saudi Arabia - Number of Cancer Cases & Deaths, 2018
Figure 2-18: Saudi Arabia - Number of Cancer Cases & Deaths by Gender, 2018
Figure 2-19: Saudi Arabia - New Diagnosed Cancer Cases by Gender (%), 2018
Figure 2-20: Saudi Arabia - Cancer Related Deaths by Gender (%), 2018
Figure 2-21: Saudi Arabia - New Diagnosed Cases by Cancer Type (%), 2018
Figure 2-22: UAE - Number of Cancer Cases & Deaths, 2018
Figure 2-23: UAE - Number of Cancer Cases & Deaths by Gender, 2018
Figure 2-24: UAE - New Diagnosed Cases by Cancer Type (%), 2018
Figure 2-25: UAE - Number of New Diagnosed Cases by Cancer Type, 2018
Figure 2-26: Kuwait - Number of Cancer Cases & Deaths, 2018
Figure 2-27: Kuwait - Number of Cancer Cases & Deaths by Gender, 2018
Figure 2-28: Kuwait - New Diagnosed Cases by Cancer Type (%), 2018
Figure 2-29: Kuwait - Number of New Diagnosed Cases by Cancer Type, 2018
Figure 2-30: Bahrain - Number of Cancer Cases & Deaths, 2018
Figure 2-31: Bahrain - Number of Cancer Cases & Deaths by Gender, 2018
Figure 2-32: Bahrain - New Diagnosed Cases by Cancer Type (%), 2018
Figure 2-33: Bahrain - Number of New Diagnosed Cases by Cancer Type, 2018
Figure 2-34: Qatar - Number of Cancer Cases & Deaths, 2018
Figure 2-35: Qatar - Number of Cancer Cases & Deaths by Gender, 2018
Figure 2-36: Qatar - New Diagnosed Cases by Cancer Type (%), 2018
Figure 2-37: Qatar - Number of New Diagnosed Cases by Cancer Type, 2018
Figure 2-38: Oman - Number of Cancer Cases & Deaths, 2018
Figure 2-39: Oman - Number of Cancer Cases & Deaths by Gender, 2018
Figure 2-40: Oman - New Diagnosed Cases by Cancer Type (%), 2018
Figure 2-41: Oman - Number of New Diagnosed Cases by Cancer Type, 2018
Figure 2-42: GCC - Total Adult Population & Diabetic Population (Million), 2017
Figure 2-43: GCC - Total Adult Population & Diabetic Population (%), 2017
Figure 2-44: GCC - Diabetic Population by Countries (Million), 2017
Figure 2-45: GCC - Diabetic Population by Countries (%), 2017
Figure 2-46: GCC - Diabetes Related Deaths by Countries, 2017
Figure 2-47: GCC - Diabetes Related Deaths by Countries (%), 2017
Figure 2-48: GCC - Diabetes Prevalence Rate by Countries (%), 2017
Figure 2-49: GCC - Age Standardized Diabetes Death Rate by Countries (Per 100,000 People), 2017
Figure 2-50: GCC - Diabetic Population (Billion), 2017, 2018 & 2045
Figure 2-51: Saudi Arabia - Total HIV Cases & Newly Diagnosed HIV Cases, 2017
Figure 2-52: Saudi Arabia - New Diagnosed HIV Cases, 2013 - 2017
Figure 2-53: Saudi Arabia - New Diagnosed HIV Cases by Gender, 2017
Figure 2-54: Saudi Arabia - New Diagnosed HIV Cases by Gender (%), 2017
Figure 2-55: Saudi Arabia - Total HIV Cases by Gender, 2017
Figure 2-56: Saudi Arabia - Total HIV Cases by Gender, 2017
Figure 2-57: Saudi Arabia - Cumulative HIV Related Deaths by Gender, 2017
Figure 2-58: Saudi Arabia - Cumulative Number of HIV Patients on Anti-retroviral Therapy, 2017
Figure 2-59: UAE - Cumulative Number of HIV Patients, 2012, 2014 & 2016
Figure 2-60: UAE - Number of New HIV Cases & Deaths, 2016
Figure 2-61: UAE - Cumulative Number of HIV Patients on Anti-retroviral Therapy, 2012, 2014 & 2018
Figure 2-62: UAE - Cumulative Number of HIV Patients, 2014 - 2018
Figure 2-63: Bahrain - HIV Associated New Cases & Deaths, 2016
Figure 2-64: Bahrain - Patients Receiving Antiretroviral Therapy (%), 2012, 2014 & 2016
Figure 2-65: Qatar - Cumulative Number of HIV Cases & Patients on Antiretroviral Therapy, 1984 - 2014
Figure 2-66: Qatar - HIV Patients on Anti-Retroviral Therapy, 1984 - 2014
Figure 2-67: Oman - Cumulative HIV Cases, 2014, 2016 & 2018
Figure 2-68: Oman - Cumulative HIV Cases by Gender, 2018
Figure 2-69: Oman - Cumulative HIV Cases by Gender (%), 2018
Figure 2-70: Oman - Cumulative HIV Cases by Age, 2018
Figure 2-71: GCC - Age Standardized Coronary Heart Disease Death Rate by Countries, 2017
Figure 2-72: GCC - CHD Related Deaths by Countries, 2017
Figure 2-73: GCC - CHD Related Deaths by Countries (%), 2017
Figure 2-74: GCC - Age Standardized Hypertension Death Rate by Countries, 2017
Figure 2-75: GCC - Hypertension Related Deaths by Countries, 2017
Figure 2-76: GCC - Hypertension Related Deaths by Countries (%), 2017
Figure 2-77: GCC - Age Standardized Stroke Death Rate by Countries, 2017
Figure 2-78: GCC - Stroke Related Deaths by Countries, 2017
Figure 2-79: GCC - Stroke Related Deaths by Countries (%), 2017
Figure 2-80: GCC - Obese Population by Countries (%), 2019
Figure 2-81: GCC - Body Mass Index by Countries, 2019
Figure 2-82: Saudi Arabia - Obesity Prevalence Rate (%), 2017 & 2022
Figure 2-83: Saudi Arabia - Obesity Prevalence Rate by Gender (%), 2017 & 2022
Figure 2-84: UAE - Prevalence Rate of Obesity & Overweight by Gender (%), 2016
Figure 2-85: UAE - Obese Adult Population (%), 2019
Figure 2-86: Kuwait - Prevalence Rate of Obesity & Overweight (%), 2016
Figure 2-87: Kuwait - Prevalence Rate of Obesity & Overweight by Gender (%), 2016
Figure 2-88: Bahrain - Prevalence Rate of Obesity & Overweight (%), 2016
Figure 2-89: Bahrain - Prevalence Rate of Obesity & Overweight by Gender (%), 2016
Figure 2-90: Qatar - Prevalence Rate of Obesity & Overweight (%), 2016
Figure 2-91: Qatar - Prevalence Rate of Obesity & Overweight by Gender (%), 2016
Figure 2-92: Oman - Obesity Prevalence Rate by Gender (%), 2016
Figure 2-93: GCC - Asthma Related Deaths by Countries, 2017
Figure 2-94: GCC - Asthma Related Deaths by Countries (%), 2017
Figure 2-95: GCC - Age Standardized Asthma Death Rate by Countries (per 100,000 People), 2017
Figure 2-96: GCC - Tuberculosis Related Deaths by Countries, 2017
Figure 2-97: GCC - Age Standardized Incidence Rate of Tuberculosis by Countries (Per 100,000 People), 2017
Figure 2-98: GCC - Asthma Related Deaths by Countries (%), 2017
Figure 2-99: GCC - Age Standardized Tuberculosis Death Rate by Countries (per 100,000 People), 2017
Figure 2-100: GCC - Influenza & Pneumonia Related Deaths by Countries, 2017
Figure 2-101: GCC - Influenza & Pneumonia Related Deaths by Countries (%), 2017
Figure 2-102: GCC - Age Standardized Influenza & Pneumonia Death Rate by Countries (per 100,000 People), 2017
Figure 2-103: GCC - COPD Prevalence Rate by Countries (%), 2018
Figure 2-104: GCC - COPD & Cystic Fibrosis Related Deaths by Countries, 2017
Figure 2-105: GCC - COPD & Cystic Fibrosis Related Deaths by Countries (%), 2017
Figure 2-106: GCC - Age Standardized COPD & Cystic Fibrosis Death Rate by Countries (per 100,000 People), 2017
Figure 2-107: GCC - Alzheimer/Dementia Related Deaths by Countries, 2017
Figure 2-108: GCC - Alzheimer/Dementia Related Deaths by Countries (%), 2017
Figure 2-109: GCC - Age Standardized Alzheimer/Dementia Death Rate by Countries (per 100,000 People), 2017
Figure 3-1: GCC - Types of Drug Registration Process
Figure 3-2: Process Map for GCC Centralized Registration
Figure 3-3: GCC - Innovative/Biological and Generic Drug Registration Fees for Evaluation Procedures (SAR/US$), 2019
Figure 3-4: GCC - Innovative/Biological and Generic Drug Registration Renewal Fees (SAR/US$), 2019
Figure 3-5: GCC - Registration Fees for Addition of New Pharmaceutical Form, New Strength & New Pack Size for Innovative/Biological Products (SAR/US$), 2019
Figure 3-6: GCC - Registration Fees for Addition of New Pharmaceutical Form, New Strength & New Pack Size for Generic Products (SAR/US$), 2019
Figure 3-7: GCC - Registration Fees for Addition of New Pharmaceutical Form, New Strength & New Pack Size for Intravenous Generic Products (SAR/US$), 2019
Figure 3-8: Saudi Arabia - Regulatory Process for Pharmaceuticals
Figure 3-9: Kuwait - Regulatory Process for Pharmaceuticals
Figure 3-10: UAE - Regulatory Process for Pharmaceuticals
Figure 3-11: Bahrain - Regulatory Process for Pharmaceuticals
Figure 3-12: Qatar - Regulatory Process for Pharmaceuticals
Figure 3-13: Oman - Regulatory Process for Pharmaceuticals
Figure 5-1: GCC - Pharmaceutical Market Size - Generic vs. Others (US$ Billion), 2018
Figure 5-2: GCC - Pharmaceutical Market Size - Generic vs. Others (%), 2018
Figure 5-3: GCC - Generic Drug Market Size (US$ Billion), 2018 - 2025
Figure 5-4: GCC - Patented & OTC Pharmaceutical Market Size (US$ Billion), 2018
Figure 5-5: GCC - Share of Patented Products in Pharmaceutical Market by Countries (%), 2016
Figure 5-6: GCC - Share of OTC Products in Pharmaceutical Market by Countries (%), 2016
Figure 5-7: GCC - Biosimilars Market Size (US$ Million), 2019 & 2025
Figure 5-8: GCC - Strategies Considered by New Biosimilars Manufacturers
Figure 5-9: Key Stakeholders for Launch of Biosimilars
Figure 6-1: Pharmaceutical Market Size - Saudi Arabia vs. Rest of GCC (%), 2018
Figure 6-2: Pharmaceutical Market Size - Saudi Arabia vs. Rest of MEA (%), 2018
Figure 6-3: Saudi Arabia - Pharmaceutical Market Size (US$ Billion), 2018 - 2025
Figure 6-4: Saudi Arabia - Pharmaceutical Market Share by Channel of Distribution (%), 2018
Figure 6-5: Saudi Arabia - Pharmaceutical Market Size by indication (%), 2018
Figure 6-6: Saudi Arabia - Number of New Product Launched by Indication, 2018
Figure 6-7: Saudi Arabia - Sales Data of Leading Pharmaceutical Products (US$ Million), 2018
Figure 6-8: Saudi Arabia - Revenue of Leading Pharmaceutical Companies (US$ Million), 2018
Figure 6-9: Saudi Arabia - Generic & Branded Pharmaceutical Market Size (%), 2018
Figure 6-10: Saudi Arabia - OTC & Prescribed Pharmaceuticals Market Size (US$ Billion), 2018
Figure 6-11: Saudi Arabia - OTC & Prescribed Pharmaceutical Market Size (%), 2018
Figure 7-1: Pharmaceutical Market Size - UAE vs. Rest of GCC (%), 2018
Figure 7-2: Pharmaceutical Market Size - UAE vs. Rest of MEA (%), 2018
Figure 7-3: UAE - Pharmaceutical Market Size by Channel of Distribution (%), 2018
Figure 7-4: UAE - Pharmaceutical Market Size (US$ Billion), 2018 - 2025
Figure 7-5: UAE - Pharmaceutical Export Market by Region (%), 2017
Figure 7-6: UAE - Pharmaceutical Export Market by Countries (%), 2017
Figure 7-7: UAE - Pharmaceutical Export Market by Products (%), 2018
Figure 7-8: UAE - Pharmaceutical Market Size by Therapeutic Indication (US$ Million), 2018
Figure 7-9: UAE - Number of New Launched Pharmaceutical Product by Indication, 2018
Figure 7-10: UAE - Growth Rate of Leading Pharmaceutical Companies (%), 2018
Figure 7-11: UAE - Pharmaceutical Market Share by Type of Products (%), 2017
Figure 7-12: UAE - Pharmaceutical Market Share by Type of Products (%), 2018
Figure 7-13: UAE - Generic Drug Market Size (US$ Million), 2017 - 2025
Figure 8-1: Pharmaceutical Market Size - Kuwait vs. Rest of GCC (%), 2018
Figure 8-2: Pharmaceutical Market Size - Kuwait vs. Rest of MEA (%), 2018
Figure 8-3: Kuwait - Pharmaceutical Market Size (US$ Billion), 2018-2025
Figure 8-4: Kuwait - Pharmaceutical Market Size by Therapeutic Indication (%), 2018
Figure 8-5: Kuwait - Sales Data of Leading Pharmaceutical Products (US$ Million), 2018
Figure 8-6: Kuwait - Pharmaceutical Market Size - MNC vs. Regional Companies (%), 2016
Figure 8-7: Kuwait - Julphar Pharmaceutical Share in Regional Pharmaceutical sales (%), 2016
Figure 8-8: Kuwait - Pharmaceutical Market Size by Leading Companies (US$ Million), 2018
Figure 8-9: Kuwait - Generic Pharmaceutical Market Share (%), 2018 & 2025
Figure 8-10: Kuwait - Pharmaceutical Market by Type of Product (%), 2018
Figure 8-11: Kuwait - Generic Drug Market Share in Total market Size (%), 2018
Figure 8-12: Kuwait - OTC Pharmaceutical Market Share (%), 2018 & 2025
Figure 9-1: Bahrain - Pharmaceutical Market Size - Bahrain vs. Rest of GCC (%), 2018
Figure 9-2: Bahrain - Pharmaceutical Market Size (US$ Million), 2018 - 2025
Figure 9-3: Bahrain - Pharmaceutical Market Size - Import vs. Total Market (US$ Million), 2018
Figure 9-4: Bahrain - Pharmaceutical market Share - Import vs. Other Market (%), 2018
Figure 9-5: Bahrain - Pharmaceutical market Share by Therapeutic Agents (%), 2018
Figure 9-6: Bahrain - Market Size by Leading Pharmaceutical Companies (US$ Million), 2018
Figure 9-7: Bahrain - Share of Generics in Total Pharmaceutical Market (%) 2018 & 2025
Figure 9-8: Bahrain - Share of OTC in Total Pharmaceutical Market (%) 2018 & 2025
Figure 9-9: Bahrain - Patented, Generics & OTC Pharmaceuticals Market Share (%), 2018
Figure 9-10: Bahrain - Patented, Generics & OTC Pharmaceuticals Market Share (%), 2025
Figure 9-11: Bahrain - Generic Pharmaceutical Market Size (US$ Million), 2018 & 2025
Figure 9-12: Bahrain - OTC Pharmaceutical Market Size (US$ Million), 2018 & 2025
Figure 10-1: Qatar - Pharmaceutical Market Size (US$ Million), 2015 - 2018
Figure 10-2: Qatar - Pharmaceutical Market Size - Qatar vs. Rest of GCC (%), 2018
Figure 10-3: Qatar - Pharmaceutical Market Size - Qatar vs. Rest of MEA (%), 2018
Figure 10-4: Qatar - Pharmaceutical Market Size (US$ Million), 2018 - 2025
Figure 10-5: Qatar - Pharmaceutical Market Size by Product Type (US$ Million), 2018
Figure 10-6: Qatar - Pharmaceutical Market Size by Product Type (%), 2018
Figure 10-7: Qatar - Pharmaceutical Market Size by Type of Product (US$ Million), 2025
Figure 11-1: Oman - Pharmaceutical Market Size (US$ Million), 2012, 2016 & 2018
Figure 11-2: Pharmaceutical Market Size - Oman vs. Rest of GCC (%), 2018
Figure 11-3: Pharmaceutical Market Size - Oman vs. Rest of MEA (%), 2018
Figure 11-4: Oman - Pharmaceutical Market Size (US$ million), 2019 - 2025
Figure 11-5: Oman - Import, Export & Other Pharmaceutical Market Size (US$ Million), 2018
Figure 11-6: Oman - Import, Export & Other Pharmaceutical Market Size (%), 2018
Figure 11-7: Oman - Share of Generics in Total Pharmaceutical Market (%) 2016, 2018 & 2025
Figure 11-8: Oman - Share of OTC in Total Pharmaceutical Market (%) 2016, 2018 & 2025
Figure 11-9: Oman - Patented, Generics & OTC Pharmaceuticals Market Share (%), 2018
Figure 11-10: Oman - Patented, Generics & OTC Pharmaceuticals Market Share (%), 2025
Figure 11-11: Oman - Generic Pharmaceutical Market Size (US$ Million), 2018 & 2025
Figure 11-12: Oman - OTC Pharmaceutical Market Size (US$ Million), 2018 & 2025
Figure 12-1: GCC - Pharmaceutical Import Market Size by Countries (US$ Billion), 2018
Figure 12-2: GCC - Pharmaceutical Import Market Size by Countries (%), 2018
Figure 12-3: GCC - Import Pharmaceutical Market Size (US$ Billion), 2016, 2017 & 2018
Figure 12-4: Saudi Arabia - Pharmaceutical Import Size (US$ Billion), 2016 - 2018
Figure 12-5: UAE - Pharmaceutical Import Size (US$ Billion), 2016 - 2018
Figure 12-6: Kuwait - Pharmaceutical Import Size (US$ Billion), 2016 - 2018
Figure 12-7: Bahrain - Pharmaceutical Import Size (US$ Million), 2016 - 2018
Figure 12-8: Qatar - Pharmaceutical Import Size (US$ Million), 2016 - 2018
Figure 12-9: Oman - Pharmaceutical Import Size (US$ Million), 2016 - 2018
Figure 12-10: GCC - Pharmaceutical Export Market Size by Countries (US$ Million), 2018
Figure 12-11: GCC - Pharmaceutical Export Market Size by Countries (%), 2018
Figure 12-12: GCC - Export Pharmaceutical Market Size (US$ Billion), 2016, 2017 & 2018
Figure 12-13: Saudi Arabia - Pharmaceutical Export Size (US$ Million), 2016 - 2018
Figure 12-14: UAE - Pharmaceutical Export Size (US$ Million), 2016 - 2018
Figure 12-15: Kuwait - Pharmaceutical Export Size (US$ Million), 2016 - 2018
Figure 12-16: Bahrain - Pharmaceutical Export Size (US$ Million), 2016 - 2018
Figure 12-17: Qatar - Pharmaceutical Export Size (US$ Million), 2016 - 2018
Figure 12-18: Oman - Pharmaceutical Export Size (US$ Million), 2016 - 2018
Figure 13-1: GCC - Number of Clinical Trials by Countries, 2019
Figure 13-2: GCC - Clinical Trials by Countries (%), 2019
Figure 13-3: GCC - Number of Clinical Trials by Status, 2019
Figure 13-4: GCC - Clinical Trials by Status (%), 2019
Figure 13-5: GCC - Number of Clinical Trial by Phase, 2019
Figure 13-6: GCC - Number of Clinical Trial by Phase (%), 2019
Figure 13-7: GCC - Numbers of Clinical Trials by Indications, 2019
Figure 13-8: GCC - Clinical Trials by Indications (%), 2019
Figure 13-9: GCC - Number of Cancer Related Clinical Trials by Countries, 2019
Figure 13-10: GCC - Cancer Related Clinical Trials by Countries (%), 2019
Figure 13-11: GCC - Number of Cancer Related Clinical Trials by Phase of Development, 2019
Figure 13-12: GCC - Number of Diabetes Related Clinical Trials by Countries, 2019
Figure 13-13: GCC - Diabetes Related Clinical Trials by Countries (%), 2019
Figure 13-14: GCC - Number of Diabetes Related Clinical Trials by Development Phase, 2019
Figure 13-15: GCC - Number of CVS Disorder Related Clinical Trials by Countries, 2019
Figure 13-16: GCC - CVS Disorder Related Clinical Trials by Countries (%), 2019
Figure 13-17: GCC - Number of CVS Disorders Related Clinical Trials by Development Phase, 2019
Figure 13-18: GCC - Number of Respiratory Disorder (Except Lung Cancer) Related Clinical trials by Countries, 2019
Figure 13-19: GCC - Respiratory Disorder (Except Lung Cancer) Related Clinical Trials by Countries (%), 2019
Figure 13-20: GCC - Number of Respiratory Disorders Related Clinical Trials by Development Phase, 2019
Figure 13-21: Saudi Arabia - Number of Clinical Trials by Development Phase, 2019
Figure 13-22: Saudi Arabia - Number of Clinical Trials by Status, 2019
Figure 13-23: Saudi Arabia - Numbers of Clinical Trials by Indications, 2019
Figure 13-24: Saudi Arabia - Clinical Trials by Indications (%), 2019
Figure 13-25: UAE - Clinical Trials in States of UAE (%), 2019
Figure 13-26: UAE - Number of Clinical Trials by Development Phase, 2019
Figure 13-27: UAE - Number of Clinical Trials by Status, 2019
Figure 13-28: UAE - Numbers of Clinical Trials by Indications, 2019
Figure 13-29: UAE - Clinical Trials by Indications (%), 2019
Figure 13-30: Kuwait - Number of Clinical Trials by Development Phase, 2019
Figure 13-31: Kuwait - Number of Clinical Trials by Status, 2019
Figure 13-32: Kuwait - Numbers of Clinical Trials by Indications, 2019
Figure 13-33: Kuwait - Clinical Trials by Indications (%), 2019
Figure 13-34: Bahrain - Number of Clinical Trials by Development Phase, 2019
Figure 13-35: Bahrain - Number of Clinical Trials by Status, 2019
Figure 13-36: Qatar - Number of Clinical Trials by Development Phase, 2019
Figure 13-37: Qatar - Number of Clinical Trials by Status, 2019
Figure 13-38: Qatar - Numbers of Clinical Trials by Indications, 2019
Figure 13-39: Kuwait - Clinical Trials by Indications (%), 2019
Figure 13-40: Oman - Number of Clinical Trials by Development Phase, 2019
Figure 13-41: Oman - Number of Clinical Trials by Status, 2019
Figure 14 1: Driving Factors for GCC Pharmaceutical Market
Figure 15-1: Challenges for GCC Pharmaceutical Market
Figure 16-1: GCC - Population Forecast by Countries (Million), 2025
Figure 16-2: GCC - Pharmaceutical Market Forecast by Countries (US$ Billion), 2025
Figure 16-3: GCC - Pharmaceutical Market Share Forecast by Countries (%), 2025
Figure 16-4: GCC - Cancer Drug Market Forecast (US$ Billion), 2018 & 2025
Figure 16-5: GCC - Generic Pharmaceutical Market Forecast (%), 2025

Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3

 Regional Pharmaceutical Companies:

  • Julphur Pharmaceuticals
  • SPIMACO Addwaeih
  • Qatar Life Pharma
  • Al Mojil Drug Company
  • Kuwait Saudi Pharmaceutical Company
  • YIACO Medical Company
  • Qatar Pharma
  • Saja Pharmaceuticals
  • Oman Pharmaceuticals
  • Taiba Pharmaceuticals
  • Gulf Biotech
  • Bahrain Pharma
  • Neopharma
  • Planet Pharmacies
  • Aljazeera Pharmaceutical Industries
  • Dallah Pharma
  • Tabuk Pharmaceuticals
  • CAD Middle-East Pharmaceutical Company
  • ACDIMA
  • AL-Mufid Pharmaceuticals

Multinational Companies:

  • Novartis
  • Amgen
  • Eli - Lilly
  • Merck
  • Pfizer
  • GlaxoSmithKline
  • Roche
  • Takeda Pharmaceuticals
  • Teva Pharmaceuticals
  • AstraZeneca
  • Genentech
  • Sanofi
Note: Product cover images may vary from those shown
Adroll
adroll